# Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

> **NCT03447808** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jennifer Woyach** · enrollment: 15 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Daratumumab
- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03447808
- **Lead sponsor:** Jennifer Woyach
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-16
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447808, "Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03447808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*